Akebia Therapeutics Stock Price (NASDAQ:AKBA)

Add to My Stocks
$7.78 $0.17 (2.23%) AKBA stock closing price Sep 18, 2018 (Closing)
Prev Close* : $7.61
Market Cap:
$434.11M
Day Low: $7.64
52 Week Low: $7.32
Open: $7.64
Volume: -
Day High: $7.88
52 Week High: $20.25
Dividend:
0.00

Latest Stock Market News

Latest Articles

Akebia Therapeutics News - From Partners

AKBA Stockcharts

View AKBA PE ratio, PS ratio stocks charts and compare with peers.
AKBA Chart
Note: Compare Akebia Therapeutics stock price history with the index and industry peers.

Akebia Therapeutics Valuation

PE ratio
(price earnings ratio)
-999.0000
PS ratio (
price to sales ratio
)
1.94
PB ratio (
price to book ratio
)
3.39

Akebia Therapeutics Returns

ROE
(return on equity)
-54%

Akebia Therapeutics Financial Ratios

Asset Turnover
0.46
Receivables Turnover
15.85
Debt to Equity
0
Dividend Yield
0%

AKBA Industry Peers

Company Price Change (%)
Biospecifics Technologies (BSTC)58.230.64 (1.09%)
Verrica Pharma (VRCA)16.460.1 (0.61%)
Ardelyx (ARDX)3.90.05 (1.3%)
Pieris Pharma (PIRS)5.280.2 (3.94%)
Keryx Biopharma (KERX)3.060.08 (2.68%)
Nephrogenex (NRXGQ)00 (0%)
Johnson & Johnson (JNJ)140.540.58 (0.41%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
ChemoCentryx (CCXI)11.521.03 (9.82%)
AcelRx Pharma (ACRX)3.750.3 (8.7%)
MELINTA THERAPT (MLNT)4.450.35 (8.54%)
Galectin Therapeutics (GALT)6.020.28 (4.88%)
GlycoMimetics (GLYC)14.580.67 (4.82%)
Achaogen (AKAO)4.280.17 (4.14%)
Concert Pharma (CNCE)13.420.51 (3.95%)
Top gainers from Medical-Drugs industry
* As of Sep 18, 2018
CompanyPriceChange (%)
MADRIGAL PHARMA (MDGL)207.321.13 (9.25%)
Tetraphase Pharmaceuticals (TTPH)2.90.16 (5.23%)
Recro Pharma (REPH)7.410.29 (3.77%)
Corcept Therapeutics (CORT)14.260.48 (3.26%)
Lannett Co (LCI)4.750.15 (3.06%)
Catalyst Pharma (CPRX)3.10.09 (2.82%)
Galmed Pharma (GLMD)12.610.24 (1.87%)
Top losers from Medical-Drugs industry
* As of Sep 18, 2018

Akebia Therapeutics Inc Stock News - Partner Headlines

Akebia Therapeutics Financial Statements

income statement20172016201520142013
Net Sales or Revenues177.98M1.53M---
Net Income-76.91M-135.74M-60.71M-37.03M-13.16M
Total Operating Expense257.89M137.99M61.5M37.93M15.93M
View Akebia Therapeutics income statement
balance sheet20172016201520142013
Total Assets364.24M300.21M142.94M110.99M34.66M
Total Liabilities244.91M232.09M11.94M6.91M3.9M
Shareholders Equity119.33M68.12M130.99M104.07M30.75M
View Akebia Therapeutics balance sheet
cash flow statement20172016201520142013
Net Increase (Decrease) in Assets Liabilities7.24M186.73M2.94M3.22M1.92M
Net Cash from (used by) Operating Activities-56.15M57.9M-52.4M-27.48M-11.33M
Increase (Decrease) in Prop Plant And Equipment-1.62M-2.66M-0.41M-0.22M-0.01M
View Akebia Therapeutics cash flow statement

Akebia Therapeutics Stock Message Board

Akebia Therapeutics stock gained 2.23%, and the last close price as of Sep 18, 2018 is $7.78 for AKBA stock. The total market value as denoted by $434.11M for Akebia Therapeutics, is the market value of the company's outstanding shares. Investors can use valuation multiples like the P/E ratio, price to sales ratio etc. for performing Akebia Therapeutics stock analysis.

For recognizing and analyzing the real performance of Akebia Therapeutics stock, it is a standard practise to adjust historical stock prices to remove gaps caused by stock splits, dividends and distributions. 437,937 shares were traded with a closing stock price of $7.78 as of Sep 18, 2018, as can be seen from Akebia Therapeutics stock quote. One can view Akebia Therapeutics stock chart to follow the stock price trend. The board of directors decide what percentage of a company's earnings will be paid out as dividends. Akebia Therapeutics stock dividend was 0.00 during the last quarter. One can observe stock price trends and check for volatility by checking Akebia Therapeutics stock price history.